“4+7”药品带量采购的效果、关键问题与对策——基于广州的实践  

Effects,Key issues and Countermeasures of"4+7"Drug Volume-Based Purchasing--Practice Based on Guangzhou

作　　者：谭清立 杨思远 李文静 张婉萍 TAN Qing-li;YANG Si-yuan;LI Wen-jing;ZHANG Wan-ping(School of Medical Business,Guangdong Pharmaceutical University,Zhongshan Guangdong 528400,China)

机构地区：[1]广东药科大学医药商学院,广东中山528400

出　　处：《卫生经济研究》2020年第4期46-50,共5页

基　　金：广东省普通高校青年创新人才类项目(2018WQNCX064);广东省医学科研基金项目(B2019233);广东省大学生创新创业训练计划项目(S20190573049)。

摘　　要：“4+7”药品带量采购对药品价格的影响显著,中标药品平均降幅达52%。目前,“4+7”药品带量采购试点也显现出一些问题,如医保支付标准还需完善、仿制药一次性评价进展缓慢导致竞标药品种类偏少、未中标药品的价格控制困难等。广州作为试点城市之一,实施了一系列应对措施,对该制度的深化改革有一定启示意义。The“4+7”drug volume-based purchasing has a significant impact on drug prices,and the winning bid drugs dropped by an average of 52%.At present,the pilots of“4+7”drug volume-based purchasing also shows some problems,such the improvement of medical insurance payment standards,fewer types of generic drugs due to the slow progress of one-time evaluation,and difficulty in controlling the price of unsuccessful bid drugs.As one of pilot cities,Guangzhou has implemented a series of countermeasures,which has some enlightenment significance.

关 键 词：药品带量采购 药品价格 仿制药一次性评价 

分 类 号：R19[医药卫生—卫生事业管理]